Biotechnology · Norwood, Massachusetts, United States
$9.68
+0.00% (+$0.00)2026-07-10
Smart-Money SignalNeutral · 51/100— Insiders are net buyers over 90 days ($28K, 8 buys vs 3 sales)
Net Income-$23.0M
EPS$-1.23
Market Cap$171.7M
Price Performance
Historical data including institutional events
Company Profile
Y
Yuval Cohen
CEO & Executive Director
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
